IMNM · Immunome Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $0 | $6.94M | $9.04M | $14.02M | — | — | — | — | |
| $16.14M | $11.72M | $12.84M | $2.72M | $5000 | -$10K | -$38K | -$96K | |
| $206.23M | $177.29M | $129.54M | $23.09M | $23.27M | $14.11M | $7.49M | $8.82M | |
| $54.24M | $43.77M | $32.96M | $19.66M | $13.63M | $11.09M | $4.78M | $1.53M | |
| — | $2.47M | $1.57M | $457K | $422K | $755K | $755K | $615K | |
| $270.47M | $231.05M | $314.84M | $123.55M | $36.9M | $25.2M | $12.26M | $10.35M | |
| -$270.47M | -$224.11M | -$305.8M | -$109.53M | -$36.9M | -$25.2M | -$12.26M | -$10.35M | |
| — | -3228.83% | -3382.37% | -781.35% | — | — | — | — | |
| — | -$221.65M | -$304.23M | -$109.07M | -$36.48M | -$24.45M | -$11.51M | -$9.73M | |
| — | — | — | — | $5000 | $493K | -$5.58M | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$254.32M | -$212.39M | -$292.96M | -$106.81M | -$36.9M | -$24.71M | -$17.84M | -$10.44M | |
| — | -3059.99% | -3240.38% | -761.92% | — | — | — | — | |
| -$254.32M | -$212.39M | -$292.96M | -$106.81M | -$37.52M | -$24.71M | — | — | |
| -$254.63M | -$212.45M | -$292.93M | -$106.78M | -$37.52M | — | — | — | |
| USD/shares | — | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 | -$5.26 | — |
| USD/shares | — | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 | -$5.26 | — |
| shares | — | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M | 3.39M | 1.09M |
| shares | — | 87.35M | 58.64M | 19.84M | 12.13M | 11.54M | 3.39M | 1.09M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 224 similar-size Biotechnology companies (of 533 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | $6,941,000 | $9,041,000 | $14,018,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | -$224,113,000 | -$305,800,000 | -$109,530,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | -3228.8% | -3382.4% | -781.4% |